May 10, 2011

Madison-based Mithridion gets orphan drug designation for leading compound

Congratulations to Mithridion, a Madison drug development company headed by MadREP board member Trevor Twose, on receiving orphan drug designation for its leading compound, MCD-386CR. 
Excerpted from the Wisconsin State Journal (May 9, 2010):

The drug is intended to treat progressive supranuclear palsy, or PSP, a degenerative brain disease that affects balance, walking, speech, cognition and eye movements.
Getting orphan drug status gives MCD-386CR seven years of market exclusivity as a treatment for PSP, if it eventually is approved by federal regulators, said Mithridion chief executive Trevor Twose.

Read the full article. 

Are you here for Main Street Bounceback Grants?
This is default text for notification bar